Mobilization of Autologous Peripheral Blood Stem Cells (PBSC) in CD20+ Lymphoma Patients Using RICE, Granulocyte-Colony Stimulating Factor (G-CSF) and Plerixafor

RICE is salvage therapy for treating CD20+non-Hodgkin lymphoma (NHL). It combined with G-CSF to collect autologous peripheral blood stem cells (aPBSC). Little data exists, though, on the combination of and Plerixafor after in mobilizing adequate number CD34 product’s immune content. We report results twenty CD20+ NHL patients RICE, were given aPBSC. The median collected was 12.92 × 10<sup>6</sup> cells/kg (range 5.44-83.76). toxicity included diarrhea (n = 5) injection-site irritation 1). Seventeen collected; fifteen did so one session. Two CLL/Richter or transformed follicular had positive-flow products. Addition increased by 2.6-9 folds cells. Sixteen went ASCT, a 7.29 infused. engraftment time post-ASCT neutrophils 12 10-19), platelets ≥20K 11 0-19) ≥50K 16.5 11-42) days. There no graft failures. In APBSC product, there evidence NK LAK lytic activity 10), only 4) both 2). Blood common day +28 post-ASCT. significant correlation between apheresis product post- ASCT relapse. RICE/G-CSF well tolerated. majority aPBSC